Advancing molecular science

Engineering safer medicines for a healthier future

Parabilis Medicines develops high-purity pharmaceutical compounds with uncompromising quality, from discovery through global distribution.

Targeted small-molecule therapies for chronic cardiovascular disease management.

Next-generation compounds addressing rising antimicrobial resistance.

Precision biologics engineered for advanced solid-tumor treatment.

Innovation

A new class of alpha-helical peptides aimed at intracellular proteins that conventional medicines could not reach.

History

Started as Fog Pharmaceuticals, on the back of a Harvard insight about the protein alpha-helix and the targets called undruggable.

Investors

$32.90 +0.33 (+1.01%) — session snapshot and price history.

Trusted by clinicians worldwide

Our compounds power treatment across 40+ markets with a proven safety record.

40+

Markets

Compounds

98%

Purity